drugset
Drugs / CF33-hNIS-antiPDL1
last change Aug 2025 re-read 3 minutes ago

CF33-hNIS-antiPDL1

targets CD274

Developed for
female breast carcinoma · triple-negative breast carcinoma
Investigated by
City of Hope Medical Center · Imugene Limited · National Cancer Institute (NCI)

Trials 1

today NCT05081492 · Ph 1
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05081492 Oct 2021 → Mar 2027 expected female breast carcinoma, triple-negative breast carcinoma City of Hope Medical Center Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as CF33-hNIS-anti-PD-L1 “CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.” PMID 38028143 ↗ Nov 2023
1

“CF33-hNIS-antiPDL1, an oncolytic orthopoxvirus” PMID 40933893 ↗ Aug 2025
Route Other “intratumorally (IT)” NCT05081492 ↗
Target CD274 “CF33-expressing hNIS/Anti-PD-L1 Antibody” NCT05081492 ↗